Kristiina Vuori

Kristiina Vuori, MD, PhD is President of the Sanford Burnham Prebys Medical Discovery Institute (SBP), Pauline & Stanley Foster Presidential Chair, and Professor at the Institute’s National Cancer Institute (NCI)-designated Cancer Center. As President of SBP, Dr. Vuori is responsible for the Institute’s academic and scientific activities. Dr. Vuori was selected as a PEW Scholar in the Biomedical Sciences in 1997 (dubbed as “20 most promising scientists in America”). She was elected to the National Academy of Inventors (NAI) in 2014. Additionally, Dr. Vuori has served in a wide variety of advisory capacities to NCI and other cancer organizations, including advisory roles for the NCI’s Developmental Therapeutics Program, Center for Strategic Scientific Initiatives, and the National Cancer Advisory Board. Dr. Vuori has served or currently serves on the Board of Directors for the American Association for Cancer Research (AACR), California Breast Cancer Research Program (CBCRP), Florida Inventors Hall of Fame and WebMD. She also serves on numerous editorial boards for scientific journals, institutional scientific advisory boards and as consultant for pharmaceutical companies. Dr. Vuori earned her MD and PhD degrees at University of Oulu, Finland. After the completion of her internship and residency, she received postdoctoral training at SBP from 1992–1995 with then-President & CEO Dr. Erkki Ruoslahti. Dr. Vuori was appointed to faculty in 1996. She was appointed Deputy Director of the Institute’s NCI-designated Cancer Center in 2003 and served as Director of the Cancer Center in 2005-2013. She served as Executive Vice President for Scientific Affairs in 2008–2010, and she has been President of the Institute since 2010. Additionally, she served as an interim CEO from 2013–2014.

Dr. Vouri’s qualifications for membership on Forian’s board of directors include:her many years of experience as a physician and an executive of a prestigious medical institutions, her involvement with early-stage biotechnology and medical companies and her prior service as a director of public companies.